Introduction
The lymphoproliferative disease of granular lymphocytes (LDGL) is a heterogeneous disorder characterized by chronic proliferation of granular lymphocytes (GLs). In the majority of cases (85%), proliferating GLs belong to the T-cell lineage and express the CD3 þ CD16 þ phenotype. However, in nearly 15% of cases, pathological GLs originate from the expansion of natural killer (NK) cells expressing the CD3 À CD16 þ phenotype. [1] [2] [3] The recent definition of a pattern of surface receptors on the GLs of LDGL patients led to the hypothesis that NK receptors (NKRs) might play a central role in priming GL proliferation in this disease. [4] [5] [6] Among the NKR family, the killer immunoglobulin-like receptors (KIRs) reportedly related to the susceptibility to NK-type LDGL. [4] [5] [6] The KIR genes are highly polymorphic and polygenic, 7 the gene content of the KIR cluster varying from individual to individual. 8 KIRs specifically recognize major histocompatibility complex (MHC) class I alleles, including groups of human leukocyte antigen (HLA)-A, HLA-B and HLA-C. 9 Fifteen KIR genes (plus two pseudogenes) have been identified, located on the chromosome 19p13.4 within the leukocyte receptor complex (LCR). 10 The genomic diversity gives rise to a high number of different possible KIR haplotypes and population studies of KIR genotypes have identified two major KIR haplotype groups (A and B haplotypes). [11] [12] [13] [14] Group A haplotypes have a unique combination of seven KIR genes with only one activating gene, KIR2DS4. This last gene is often substituted by an allelic variant, named KIR1D, characterized by a 22 base pair deletion, resulting in a protein product truncated within the transmembrane domain and unable to provide any function. As a consequence, KIR1D leads to an A haplotype lacking all functional activating KIR receptors. 15 In contrast, group B haplotypes are more variable and characterized by the presence of more than one activating KIR gene. A high number of different KIR haplotypes differing in the number and content of their KIR genes, and further diversified through allelic polymorphism, 7, [15] [16] [17] [18] [19] exists in the human population. Given the synergy between these components of KIR diversity, the likelihood that two unrelated individuals have an identical KIR genotype is o0.01. 20 Comparison of ethnic populations (Australian aboriginals, Africans, Indians, Caucasians and Japanese) shows that there are considerable divergence and population-specifity in KIR haplotypes and genotypes, 14, 17, 21 usually dependent on differences in distribution of group A and B haplotypes.
The mechanism through which NK cells are induced to proliferate during NK-LDGL pathogenesis is still a matter of debate. Accumulating data suggest that exogenous agents, in particular viruses, might play a role. 1, 2, [22] [23] [24] [25] The finding that cells, which usually express activating KIRs, are positively selected in LDGL patients 4 indicates that these receptors may be directly involved in the priming of GL proliferation. Using PCRbased sequence-specific primers (PCR-SSP), in this study we investigated whether a bias toward the presence of activating KIRs was detectable in patients as compared with healthy individuals. We also compared genotypes of patients and controls to evaluate whether a putative genetic background predisposing to development of NK-type LDGL might be detected. The data obtained suggest that the susceptibility to this disease may be influenced by KIR genotype and in particular by the presence of a considerable number of activating genes.
Materials and methods

Patients and control donors
Thirty-five patients (22 males and 13 females; median age 57 years, range 27-73; all caucasians) with NK-LDGL were studied. In all cases, a chronic lymphocytosis, lasting more than 6 months and sustained by at least 2000 GLs/mm 3 , was present in the peripheral blood. 1 The time of diagnosis ranged from 12 months to 241 months before study (mean 73.8 months). Four patients were lost during follow up (after 16, 35, 46 and 67 months, respectively). Three patients died, (two cardiovascular accidents and one lung cancer) after 37, 45 and 88 months of follow-up. At the time of the study, two patients had received steroid treatment (i.e., No. 1 and No. 4) for associated diseases (myositis and nephrosic syndrome, respectively). All patients were affected by LDGL characterized by a proliferation of CD3-CD16
þ NK cells (range, 40-85%). The median absolute neutrophil count (ANC), hemoglobin (Hb) and platelets were 2.7 Â 10 9 /l (range 0.5-9.1 Â 10 9 /l), 12,8 g/dl (range 9.3-16.3 g/ dl) and 233 Â 10 9 /l (range 49-445 10 9 /l), respectively. Three patients had anemia, whereas neutropenia and thrombocytopenia were observed in eight and six patients, respectively. In contrast, in two different patients neutrophilia and thrombocytemia were observed. Two patients had splenomegaly, whereas hepatomegaly and lymphadenopathy were observed in three and four cases, respectively.
All the experiments were also performed on 50 healthy donors (31 males and 19 females; median age 39 years, range 25-53; all caucasians) representative of the control population. All healthy controls were collected from the Northeastern of Italy (blood banking donors).
KIR genotyping
Peripheral blood lymphocytes (PBLs) were obtained from patients or healthy donors by Ficoll-Hypaque gradient centrifugation.
Genomic DNA was extracted from 20 Â 10 6 PBL using the Genomic DNA Purification kit (Gentra Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
The PCR-SSP typing was used to detect the KIR genotype of LDGL patients and controls. To confirm our results, we repeated the KIR genotype analysis with a multiplex PCR-SSP that employed a different primer set provided by JY Sun et al.
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The validity of the PCR typing systems was demonstrated by application of both KIR typing methods to the genomic DNA of a representative cell line, the CF996 (ECACC, Salisbury, UK). Moreover, PCR assays were repeated in a subset of patients, obtaining a reproducibility of 100%. More specifically, 23 primer pairs were used to amplify 15 KIR genes and their allelic variants. 4 Volume reactions of 15 ml were prepared to include 30 ng of DNA, 1.5 ml 10Â PCR buffer, 1.5 mM magnesium chloride (MgCl 2 ), 0.2 mM deoxyribonucleoside triphosphates (dNTPs), 0.2 U/Taq gold (Applied Biosystems, Foster City, CA, USA), 0.4 mM of each primer, and 1% dimethyl sulfoxide (DMSO). To amplify KIR2DL5a, 2DL5b and 2DS1 we used 0.8 mM of each primer, water in place of DMSO and a reaction volume of 30 ml. Amplifications of KIR2DS1a, 2DS5a and 3DL2 were carried out using the following procedure: initial denaturation of 10 min at 951C; then 10 cycles of 35 s at 951C, 45 s at 621C and 90 s at 721C, followed by 30 cycles of 30 s at 951C, 45 s at 601C and 90 s at 721C. To amplify KIR2DL4, 2DL5a, 2DL5b and 2DS1b we used the following program: an initial denaturation of the Taq at 951C for 10 min followed by 40 cycles of 30 s at 951C, 45 s at 651C, and 1 min 30 s at 681C, followed by 681C for 7 min. For the rest of KIR genes we used an initial denaturation of the Taq at 951C for 10 min followed by 35 cycles of 30 s at 951C, 45 s at 551C, and 1 min 30 s at 681C, followed by 681C for 7 min. All the reactions were performed in a GeneAmp PCR system 9600 thermal cycler (Applied Biosystems). PCR products were analyzed for the presence or absence of an electrophoretic specific band in 1% agarose gel stained with ethidium bromide, visualized by ultraviolet light and documented with Image Master (Amersham Pharmacia Biotech, Sweden). The sequences of the primers used in this study are listed in Table 1 . For many KIR genes, two different primer sets were used to establish the presence or absence of the gene. In addition, primer sets were used to accurately identify KIR2DS4 and distinguish it from the novel gene KIR1D, which contains a 22-bp deletion in D2, leading to a frameshift and premature stop codon, with a predicted protein product truncated just within the transmembrane domain.
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Different primers sets were also used for KIR2DL5 subtyping to distinguish between expressed and non-expressed variants. In particular, primers labeled 2DL5a amplify the expressed variants and primers labeled 2DL5b identify the non-expressed variants. 27 For multiplex PCR-SSP analysis, 14 primer pairs were assigned to four multiplex reactions, resulting in 15 amplicons for detecting all functional KIR genes. PCR amplifications were performed in 10 ml of reaction solution including AmpliTaq Gold enzyme (0.6 U/10 ml) and its buffer, Mg 2 þ (2.25 mM), dNTP mixtures (0.25 mM each) (Applied Biosystems), primers (0.1-0.8 mM), and DNA template (15 ng/10 ml). The basic PCR protocol is one hold cycle at 951C, 10 min followed by three cycles of 20 s at 951C, 60 s at 681C; then, 30 cycles of 20 s at 951C, 40 s at 651C, 20 s at 721C and final extension of 5 min at 721C. The PCR products (10 ml) were separated by electrophoresis on a 3% agarose gel in 0.5 Â TBE at room temperature using voltage gradients of 7 V/cm for 40 min. Results were visualized by ultraviolet light and documented with Image Master (Amersham Pharmacia Biotech).
Phenotypic evaluation
The commercially available monoclonal antibodies (mAbs) used in this study were obtained from Becton Dickinson (Sunnyvale, CA, USA) and included Leu4 (anti-CD3), Leu11c (anti-CD16) and isotype-matched control reagents. The following mAbs were kindly provided by Moretta (Genova, Italy): EB6 (IgG1, anti-KIR2DL1 and anti-KIR2DS1), GL183 (IgG1, anti-KIR2DL2, anti-KIR2DL3 and anti-KIR2DS2), FES172 (IgG2a, anti-KIR2DS4), Z27 (IgG1, anti-KIR3DL1 and anti-KIR3DS1) and Q66 (IgM, anti-KIR3DL2). The expression of the above quoted antigens on GLs was assessed by flow cytometry analysis using direct or indirect immunofluorescence assays. The analyses were performed on freshly recovered GLs. Briefly, cells were stained with the appropriate mAbs either unlabeled or labeled; staining with unlabeled mAb was followed by phycoerythrin (PE)-or fluorescein isothiocyanate (FITC)-conjugated isotypespecific goat antimouse second reagent (Southern Biotechnology, Birmingham, AL, USA or Caltag, Burlingame, CA, USA). A PE-Cy5 CD16 and APC CD3 gate was set and the status of the antigens of interest was analyzed only on CD3-CD16 þ -gated cells. For FACS analysis, 1 Â 10 4 cells were acquired and the analyses were determined by overlaying the histograms of samples stained with the different reagents. Stained cells were scored using a FACScalibur analyser (Becton Dickinson). Samples were analyzed by four-color cytofluorimetric analysis and data were processed using CELLQuest software (Becton Dickinson).
HLA typing
HLA typing was determined using a PCR-SSP kit (GenoVision, Sweden) according to manufacturer's instructions. For each sample, 96 PCRs were performed and the amplification products were analyzed on 2% agarose gels.
The genetic mismatch between KIR genes and HLA-I was defined as the presence of a discrete KIR gene and the lack of the related HLA-I ligand. More specifically, KIR3DL2 recognizes the A3 and/or A11 allotypes, consequently, lack of HLA-A3 or -A11 combined with the presence of KIR3DL2 can be considered a KIR3DL2 mismatch. Similarly, KIR3DL1 interacts with the Bw4 epitopes; presence of two Bw6 epitopes combined with the presence of KIR3DL1 would result in a mismatch. KIR2DL2), 2DL3 and 2DS2 all interact with group 1 HLA-C molecules, which have a lysine residue in position 80. The presence of any of these three KIR genes and the absence of a group one HLA-C allele will result in a mismatch. Similarly, KIR2DL1 and 2DS1 interact with group two HLA-C molecules, those having an asparaginyl residue in position 80. HLA-C group 1 homozygosity combined with the presence of KIR2DL1 and 2DS1 would result in a mismatch. 28 To define Group one HLA-C, Group two HLA-C and Group HLA-Bw4 we referred to Ruggeri et al.
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More specifically, Group one HLA-C includes the following alleles: Cw1 (all), Cw3 (all but C*0307, C*0310 and C*0315), Cw7 (all but C*0707 and C*0709), Cw8 (all), Cw12 (all but C*1205, C*120401, C*120402), Cw13 (all), Cw14 (all, but C*1404), C*1507 and Cw16 (all but C*1602). Group two HLA-C includes these alleles: Cw2 (all), C*0307, C*0315, Cw4 (all), Cw5 (all), Cw6 (all), C*0707, C*0709, C*1205, C*120401, C*120402, Cw15 (all but C*1507), C*1602, Cw17 (all) and Cw18 (all). 
Statistical analysis
Observed KIR gene frequencies were determined by direct counting. KIR locus frequencies (KLFs) for the putative loci were estimated by the formula KLF ¼ 1ÀO(1Àf); 16 where f is the observed frequency of a particular KIR sequence in a population. Differences between NK-LDGL patients and controls in the distribution of expected and observed gene frequencies were estimated by w 2 -test and Yates-corrected P-values (P c ) were subjected to correction for the number of KIR genes analyzed. The comparison of the gene content more frequent in the group of patients versus that of controls was estimated using Mann-Whitney test.
Results
KIR locus profiles
The KIR genes of 35 NK-LDGL patients and 50 healthy individuals analyzed by PCR-SSP are reported in Tables 2 and  3 . In line with previous data obtained in Caucasian populations, all individuals were scored as KIR2DL4
þ , KIR3DL2 þ and KIR3DL3 þ , and KIR2DL2 was found always to segregate with KIR2DS2. All genotypes possessed a gene encoding a group 1 HLA-C-specific inhibitory KIR, which was either KIR2DL1, KIR2DL2 or KIR2DL3 and contained at least one activating KIR gene.
Genotypes contained between seven and 15 genes (KIR2DS4 and KIR1D were calculated as one gene because they are alleles of the same locus). The comparison of gene contents of patients and controls showed a mean of 10 genes in controls and 11 genes in patients. The difference between the two groups was not statistically significant, but when the genotype frequency was taken into account, we found that the most frequently found gene content was eight in controls and 14 in patients (Figure 1 , panels a and b, respectively) indicating that genotypes with a higher number of genes were more frequent in patients than in controls (Po0.05).
Our results in the control group were unexpected as in the literature the most frequently found gene content is represented by seven genes. 15, 30 This is almost entirely owing to the high frequency of group A haplotype homozygotes reported in Caucasian populations. In fact, all the other genotypes, which are either heterozygous combinations of group A and B haplotypes or homozygous combinations of group B haplotypes, consist of more than seven KIR genes. This is owing to the highpresence of the activating genes, both in our series of patients and surprisingly also in controls.
Frequencies of KIR genotype profiles
Previous reports found that the group A haplotype in the homozygous state is the most frequent genotype in Caucasian populations. Uhrberg et al. 30 reported that group A genotype (i.e. individuals homozygous for two group A haplotypes) in the Caucasian population is detectable every third individual. In patients under study, type A genotype was found only in one patient (frequency ¼ 0.03) indicating that this genotype is extremely rare in LDGL patients. Surprisingly, in the control group, type A genotype was detected in six cases (frequency ¼ 0.12), which represents a considerably lower frequency than expected. We also observed a considerable polymorphism of genotypes belonging to group B, which is characterized by the presence of multiple activating KIRs.
Our data in the control group recognized 34 different KIR genotypes, 24 of which appeared once, whereas the remaining 10 genotypes were observed two to four times each (Table 2 ). In the patient group, 26 different KIR genotypes were demonstrated, 16 unique and seven observed from two to three times (Table 3 ). All KIR genotypes in our study groups were determined according to the model of Hsu et al., 11 which includes the PCR typing of recently found genes KIR1D and KIR2DL5. Some individuals in each group shared the same KIR genotype (Tables 2 and 3 ). Interestingly, the recurrent genotypes observed in the patient group were not found in the control group and this was also the case of the recurrent genotypes observed in the control group. Among the unique genotypes we found two genic profiles shared by the two groups (pt no 19 with Considering the group A genotype, it is stated that the identification of KIR1D led to the distinguishing of haplotype A-1D from haplotype A-2DS4. 15 According to this classification, we found that two controls displayed a type A genotype with a heterozygous combination of these two haplotypes and four controls and one patient with haplotype A-1D in homozygous state.
Frequency of individual KIR genes
As expected, the three anchor genes (KIR2DL4, 3DL2 and 3DL3) were consistently found in both groups under study (100% of cases). Considering the activating genes, we observed that their frequencies were higher in patients than in healthy individuals, suggesting that patient genotypic profiles are characterized by a higher presence of activating KIRs (Figure 2 ). These data were not statistically significant, possibly owing to the low number of individuals taken into account.
This difficulty cannot be overcome, given the low frequency of disease. Concerning inhibitory genes, the frequencies were quite similar among the two groups, with the only exception being the frequencies of KIR2DL5a and 2DL5b which were consistently detected in patients, as compared to controls (Figure 2 ) (Po0.01). It is worth emphasizing that 2DL5b represents a group of variants which are not expressed, therefore its high frequency does not lead to functional consequences. 27 The presence of this high frequency of KIR genes in patients might be a specific feature of the genetic repertoire of the subjects with NK-LDGL.
KIRs expression in LDGL patients
To obtain data on the phenotypic profile of NK cell expansions in LDGL, PBLs from the 35 patients under study and from 50 healthy donors were evaluated by flow cytometry for the expression of a panel of KIRs. Our results are reported in Table 4 where the data of all patients are shown. We tried to determine whether a discrete expression of one or more KIR could be detected in each patient's NK cell population. As in a polyclonal NK population, each KIR can be normally present in a relevant percentage of cells, ranging from 25 to 35%, 4 we considered as positive the expression of a specific KIR in more than 20% of NK cells. As a matter of fact, this percentage can be reasonably accepted in order to include the large majority of abnormal cells expressing the relevant KIR. A percentage lower than 20% of NK Table 3 KIR locus profiles observed in the patient group cells positive for a specific KIR, although of potential interest, cannot be considered as representative of proliferating NK cell population. One or more of the KIRs antigens were expressed in 25 of 35 cases, more specifically EB6 (anti-KIR2DL1 and anti-KIR2DS1) was expressed in 11 cases, GL183 (anti-KIR2DL2, anti-KIR2DL3 and anti-KIR2DS2) in 15 cases, FEST172 (anti-KIR2DS4) in eight cases, Z27 (anti-KIR3DL1 and anti-KIR3DS1) in four cases and Q66 (anti-KIR3DL2) in one case.
KIR/HLA-I matching
HLA-typing was performed in 29 patients. At genetic level, we found that 27 patients lacked the HLA-I ligand for the corresponding KIR gene, whereas only two patients displayed a KIR/HLA-I match (Table 4) . On the other hand, considering HLA class I ligands, the presence of at least one specific KIR gene was demonstrated in each case. This is the consequence of the high frequency of individual KIR genes with a specific HLA-I ligand ( Figure 2 ). However, when phenotypic KIR expression was considered, a KIR-HLA-I mismatch was demonstrated in nine out of the 19 patients, who expressed one or more of the KIR antigens (GL183, EB6, Z27 and Q66), whereas in 10 patients, the lack of expression of KIR responsible of genetic mismatch was the reason for the missing of phenotypic mismatch. Similarly, in 10 patients who did not express any of the above KIRs, no mismatch was detectable at phenotypic level.
No relevant clinical differences could be demonstrated in the two groups of patients, that is, patients with phenotypic KIR/ HLA-I matching versus patients with mismatching.
Discussion
In this study, we showed that the KIR genotype of NK-LDGL patients was biased toward the presence of genes coding for activating KIRs. We also demonstrated that several genotypic peculiarities characterized the patients.
Although the evaluation of KIR expression using flow cytometry (Table 4) represents an important tool in the diagnosis of NK-LDGL 4 offering the opportunity to distinguish between pathologic and normal NK cells, this analysis does not allow to distinguish between NK cells bearing activating or inhibitory receptors. Previous phenotypic and functional studies suggested KIR genotype in NK-LDGL E Scquizzato et al that a crucial step in the development of NK-type LDGL might be the selection and the expansion of the rare NK cell subset bearing activating KIRs, instead of the more common NK cells expressing inhibitory KIRs, indicating that these receptors may be directly involved in the priming of the NK proliferation. 4, 5, 31 Although the mechanism that induces NK cells to proliferate during NK-LDGL development is still a matter of debate, accumulating data suggest that exogenous agents, in particular, viruses might play a role. 25, [32] [33] [34] Thus, the recognition of virally infected cells through activating KIRs may represent the triggering event at the onset of NK proliferation. 4, 35 According to this interpretation, one may ask whether those individuals who are carrying a KIR genotype characterized by the presence of a large number of genes coding for activating KIR may be more likely to develop NK-LDGL. For this reason, we focused our analysis on the KIR gene profile, which is characterized by variable gene content and allelic polymorphism achieving a high level of diversity from individual to individual. Our data demonstrated that NK-LDGL patients are usually equipped with KIR genotypes containing multiple activating KIR genes. This result was obtained in a large number of patients suffering from this rare disease and strongly supports the above-mentioned suggestion that genotypic profile is crucial for the development of NK-type LDGL. The existence of an activating KIR pattern was already suggested on functional grounds in previous reports in a low number of patients, [4] [5] [6] but it has been definitively confirmed in this study on the basis of genotypic profile.
The analysis of the gene numbers accounting for each genotype revealed that genotypes with a higher number of genes were more frequent in patients than in controls. This figure was almost entirely owing to the increased presence of the activating KIR genes. In fact, the inhibitory gene number is more conserved than that of activating genes. These data are also supported by the analysis of the frequency of individual KIR genes, indicating a bias towards the presence of the activating KIR genes. Interestingly, we also observed a putative peculiarity of the KIR gene repertoire of individuals with NK-LDGL. More specifically, the inhibitory KIR2DL5, in its two allelic variants, appeared to be detected with higher frequency in patients. As no known surface antigen is associated with this gene, it is still unknown whether this finding has biological significance. As a matter of fact, the KIR2DL5 gene has been only recently identified, its ligand has not yet defined and one of its variants is not expressed. 27, 36, 37 In the genotypic profile analysis, together with different and unique genotypes we also noted that some individuals in each group shared the same KIR genotype from one to four times. Although this feature was found in both groups and it has been previously reported in normal Caucasian populations, it is interesting to note that the recurrent type B genotypes observed in patients were not found in controls and vice versa. In fact, the two groups shared only two type B gene profiles classified as unique. These data strongly indicate that some genotypes are discrete and characteristic of NK-type LDGL patients.
The putative relevance of KIR/HLA-I interactions for NK cells proliferation still represents a matter of debate. Published data indicate that the presence of specific KIR-ligands mismatches does not correlate with the diagnosis of disease, 38 although an association has been reported with the presence of symptoms. 39 As in the large majority of patients under study, the disease follows an indolent behavior, this association can not be verified. However, it can be hypothesized that KIR/HLA-I matching might correlate with initial steps of proliferation. To test this issue, we performed HLA genotyping analysis of 29 NK-LDGL patients under study (Table 4) . KIR/HLA-I genetic mismatch has been commonly detected in healthy individuals, being KIR3DL2/HLA -A3, -A11 the most frequent mismatch (reaching 58%). 28 Considering the genetic KIR/HLA-I relationship, it is evident that the majority of patients had a KIR/HLA-I mismatch. This feature may suggest a hypothetical role of the KIR/HLA-I mismatch in the pathogenesis of the disease. As a matter of fact, the only two symptomatic cases among our series were included in this group. An intriguing issue rests the evaluation of KIR expression. As KIR gene expression on NK cells is regulated both at transcriptional and post-transcriptional levels, the condition that a gene could not result in the production of the corresponding KIR protein is clearly a possible event. Accordingly, the missing expression of a specific KIR antigen on cell surface might result in the lack of phenotypic mismatch, even in the presence of a genetic mismatch. When the surface expression of KIR was considered, nearly 37% of patients with a genotypic mismatch showed full KIR/HLA-I matching. Studies are in progress to test the regulation of KIR gene expression in patients with LDGL (paper in preparation). We observed only one patient versus six controls who displayed homozygous type A genotype, indicating the significantly low frequency of this genotype (3%) in LDGL patients. On the other hand, the controls showed a higher presence of type A genotype, accounting for 12% of all genotypes. This result however is not consistent with literature data reporting that the frequency of haplotype A in the homozygous state is a very common condition in Caucasian populations, accounting for roughly 30% of normal individuals. 30 Moreover, it is interesting to note that haplotype A in homozygous state showed extremely high frequencies in the Chinese Han population (58,7%) similar to that in Japanese (56%), whereas in Australian Aborigines only a single individual out of 67 expressed a group A genotype. 21 It should be pointed out that several groups have demonstrated that KIR genotypes were different in different ethnic populations and among Caucasian people. 14, [16] [17] [18] As a matter of fact, studies concerning KIR genotype in the Italian population do not still exist. Although our analysis is not a population study, it is interesting to consider that all healthy controls enrolled for this study are collected from the NorthEastern Italy, where a high frequency of NK-LDGL cases occurs (personal observation derived from a nationalbased study, coordinated by our Hematology Department, in which all Italian cases of this rare disorder are collected). These observations suggest that the high incidence of NK-LDGL in the NorthEastern Italy could be linked to the presence of genetic factors predisposing the development of this disease. A similar concept has been postulated to explain the regional high incidence of Helicobacter pylori-related mucosa-associated lymphoid tissue lymphoma in a small area of Northern Italy. 40, 41 Based on these preliminary results, studies are currently in progress to test this hypothesis in a larger number of cases.
In conclusion, our results show that the NK-LDGL patient genotype is characterized by the presence of multiple activating genes. It is also suggested that a genetic background might exist which favors the development of the NK-LDGL and accounts for the different frequency of this disease in different geographical areas.
